Adaptation of hepatic ammonia metabolism after chronic valproate administration in epileptics treated with phenytoin. 1985

C Marescaux, and J M Warter, and C Brandt, and L Rumbach, and G Micheletti, and G Chabrier, and M Imler

The effects of phenytoin (PHT) on the modifications of ammonia (NH+4) metabolism caused by sodium valproate (VPA) are here studied in order to identify the drug combinations susceptible of evoking stuporous states in epileptics, a rare condition attributed to a hyperammonemic encephalopathy induced by VPA. During chronic treatment with PHT or VPA-PHT, the acute injection of VPA increases the kidney's output of NH+4. During chronic PHT treatments, the acute injection of VPA modifies the liver's NH+4 metabolism and the arterial hyperammonemia is high (mean = 90 mumol/l). During chronic VPA-PHT treatments, the acute injection of VPA does not affect the hepatic NH+4 metabolism, suggesting that adaptation occurs, and the arterial hyperammonemia is moderate (mean = 60 numol/l). Disturbances of the hepatic adaptive mechanisms may explain certain complications observed during multiple-drug regimens.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000222 Adaptation, Physiological The non-genetic biological changes of an organism in response to challenges in its ENVIRONMENT. Adaptation, Physiologic,Adaptations, Physiologic,Adaptations, Physiological,Adaptive Plasticity,Phenotypic Plasticity,Physiological Adaptation,Physiologic Adaptation,Physiologic Adaptations,Physiological Adaptations,Plasticity, Adaptive,Plasticity, Phenotypic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

C Marescaux, and J M Warter, and C Brandt, and L Rumbach, and G Micheletti, and G Chabrier, and M Imler
January 1980, Folia psychiatrica et neurologica japonica,
C Marescaux, and J M Warter, and C Brandt, and L Rumbach, and G Micheletti, and G Chabrier, and M Imler
July 1995, Indian journal of physiology and pharmacology,
C Marescaux, and J M Warter, and C Brandt, and L Rumbach, and G Micheletti, and G Chabrier, and M Imler
September 1977, Epilepsia,
C Marescaux, and J M Warter, and C Brandt, and L Rumbach, and G Micheletti, and G Chabrier, and M Imler
August 1982, British journal of clinical pharmacology,
C Marescaux, and J M Warter, and C Brandt, and L Rumbach, and G Micheletti, and G Chabrier, and M Imler
June 1983, Italian journal of neurological sciences,
C Marescaux, and J M Warter, and C Brandt, and L Rumbach, and G Micheletti, and G Chabrier, and M Imler
February 1982, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
C Marescaux, and J M Warter, and C Brandt, and L Rumbach, and G Micheletti, and G Chabrier, and M Imler
January 1978, Neurologia i neurochirurgia polska,
C Marescaux, and J M Warter, and C Brandt, and L Rumbach, and G Micheletti, and G Chabrier, and M Imler
December 1964, Epilepsia,
C Marescaux, and J M Warter, and C Brandt, and L Rumbach, and G Micheletti, and G Chabrier, and M Imler
October 1984, Epilepsia,
C Marescaux, and J M Warter, and C Brandt, and L Rumbach, and G Micheletti, and G Chabrier, and M Imler
November 1985, Life sciences,
Copied contents to your clipboard!